Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

220.97 -3.78 (-1.68%)
Streaming Delayed Price Updated: 12:52 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 403,426
Open 225.29
Bid (Size) 220.89 (1)
Ask (Size) 221.17 (2)
Prev. Close 224.75
Today's Range 220.45 - 225.29
52wk Range 161.65 - 275.00
Shares Outstanding 50,396,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Landscape: 7 Takes On Charles River
Via Benzinga
CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024
CRL stock results show that Charles River beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-5.67%
-5.67%
1 Month
-4.89%
-4.89%
3 Month
-9.95%
-9.95%
6 Month
+16.57%
+16.57%
1 Year
+12.30%
+12.30%

More News

Read More
Charles River Laboratories Announces First-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
The 7 Best Growth Stocks to Buy in May 2024
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evaluating Charles River: Insights From 7 Financial Analysts
Via Benzinga
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River to Perform Plasmid Production for Ship of Theseus
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Barclays Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
The Top 3 Healthcare Stocks to Buy in March 2024
Via InvestorPlace
Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy?
Via InvestorPlace
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months
Via Investor's Business Daily
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
From Charles River Laboratories International, Inc.
Via Business Wire
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.